Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic

European Journal of Pharmacology

Volumn 515, Issue 1-3, 2005, Pages 10-19

  Tadori, Yoshihiro ^a   Miwa, Takashi ^a   Tottori, Katsura ^a   Burris, Kevin D ^b,c   Stark, Arlene ^b   Mori, Toyoki ^a   Kikuchi, Tetsuro ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b BRISTOL MYERS SQUIBB   (United States)

^c Palatin Technologies   (United States)

Author keywords

Antipsychotic; Aripiprazole; Dopamine D2 receptor; Partial agonist; Receptor density; Schizophrenia

Indexed keywords

7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; ARIPIPRAZOLE; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FORSKOLIN; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PARTIAL AGONIST; PRECLAMOL; RISPERIDONE; TERGURIDE; ZIPRASIDONE;

ANIMAL CELL; ARTICLE; CHO CELL; COMPARATIVE STUDY; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DNA, COMPLEMENTARY; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FORSKOLIN; HALOPERIDOL; HUMANS; LISURIDE; PIPERAZINES; PIPERIDINES; QUINOLONES; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RISPERIDONE; TRANSFECTION; TRITIUM;

EID: 20344400385     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.02.051     Document Type: Article

References (31)

1. O. Benkert, F. Muller-Siecheneder, and H. Wetzel Dopamine agonists in schizophrenia: a review Eur. Neuropsychopharmacol. 5 1995 43 53 (Suppl)
2. M.A. Bradford Rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein dye-binding Anal. Biochem. 6 1976 3177 3188
3. 2 receptors J. Pharmacol. Exp. Ther. 302 2002 381 389
4. 2L receptors Neuropsychopharmacology 27 2002 723 726
5. 2 receptor: two molecular forms generated by alternative splicing EMBO J. 8 1989 4025 4034
6. A. Enz, M. Goldstein, and E. Meller Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum Mol. Pharmacol. 37 1990 560 565
7. R.F. Furchgott, and P. Bursztyn Comparison of dissociation constants and of relative efficacy of selected agonists acting on parasympathetic receptors Ann. N.Y. Acad. Sci. 144 1967 882 898
8. S. Hjorth, A. Carlsson, D. Clark, K. Svensson, H. Wikstrom, D. Sanchez, P. Lindberg, U. Hacksell, L.E. Arvidsson, A. Johansson, and J.L.G. Nilsson Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP Psychopharmacology 81 1983 89 99
9. 1A receptor Eur. J. Pharmacol. 441 2002 137 140
10. J.M. Kane, W.H. Carson, A.R. Saha, R.D. McQuade, G.G. Ingenito, D.L. Zimbroff, and M.W. Ali Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder J. Clin. Psychiatry 63 2002 763 771
11. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am. J. Psychiatry 157 2000 514 520
12. W. Kehr Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism Eur. J. Pharmacol. 97 1984 111 119
13. T.P. Kenakin Pharmacologic Analysis of Drug-Receptor Interaction 1997 Lippincott-Raven Philadelphia
14. 2 short isoform in dopaminergic pathways Proc. Natl. Acad. Sci. U. S. A. 95 1998 7731 7736
15. 2 receptor antagonistic activity J. Pharmacol. Exp. Ther. 274 1995 329 336
16. M. Kozak An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs Nucleic Acids Res. 15 1987 8125 8148
17. A.C. Lahti, M.A. Wiler, P.K. Corey, R.A. Lahti, A. Carlsson, and C.A. Tamminga Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia Biol. Psychiatry 43 1998 2 11
18. C.P. Lawler, C. Prioleau, M.M. Lewis, C. Mak, D. Jiang, J.A. Schetz, A.M. Gonzalez, D.R. Sibley, and R.B. Mailman Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 20 1999 612 627
19. 125I]2′-iodospiperone Psychopharmacology 110 1993 27 36
20. 2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites Proc. Natl. Acad. Sci. U. S. A. 100 2003 4305 4309
21. S.R. Marder, R.D. McQuade, E. Stock, S. Kaplita, R. Marcus, A.Z. Safferman, A. Saha, M. Ali, and T. Iwamoto Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials Schizophr. Res. 61 2003 123 136
22. R.D. McQuade, K.D. Burris, and S. Jordan Aripiprazole: a dopamine-serotonin system stabilizer Int. J. Neuropsychopharmacol. 5 Suppl. 1 2002 S176
23. E. Meller, K. Bohmaker, Y. Namba, A.J. Friedhoff, and M. Goldstein Relationship between receptor occupancy and response at striatal dopamine autoreceptors Mol. Pharmacol. 31 1987 592 598
24. 2 dopaminergic inhibition of prolactin release in vivo and in vitro J. Pharmacol. Exp. Ther. 257 1991 668 675
25. M.J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J. Boutin, and A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I: a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther. 303 2002 791 804
26. 2, receptor subtypes J. Pharmacol. Exp. Ther. 303 2002 815 822
27. 2 receptors in signal transduction and behavior Crit. Rev. Neurobiol. 11 2&3 1997 121 142
28. 2 receptors, yet occupy high levels of these receptors Mol. Psychiatry 3 1998 123 134
29. 2 receptors Nature 408 2000 199 203
30. 2 receptor antagonist Life Sci. 42 1988 1941 1954
31. 11C]raclopride Neuropsychopharmacology 27 2002 248 259